Blog December 2, 2020
New FDA Draft Guidance Sheds Light On Regulation of 'Mobile Medical Apps' and Other Software
- Person title
BNA Medical Devices Law & Industry Report Vol. 5, No. 16
By: Keith Barritt
FDA regulatory attorneys have appreciated for decades that software alone can be considered a "medical device.'' As early as 1989 the FDA issued a draft policy on the regulation of software. However, in 2005, recognizing that medical software had advanced by leaps and bounds since 1989 and would likely continue to evolve rapidly, the FDA took the rather unusual step of rescinding its 1989 draft policy, erasing it completely from the website, leaving industry somewhat in the dark as to when software would be considered a regulated device.
With the growing phenomenon of medical device applications for smartphones and other mobile platforms, in late July the FDA released a new draft guidance on the regulation of "mobile medical applications'' (5 MELR 476, 7/27/11). This document is a very welcome effort to bring clarity to the issue of when a mobile phone app is subject to FDA regulation as a "medical device.'' Public comments are due by October 19, 2011.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.
Blog December 9, 2019
Blog July 26, 2019
Heightened Scrutiny of Specimens of Use at U.S. Trademark Office
Blog July 3, 2019
Legal Alert: New Rule Requires Foreign-Domiciled Trademark Applicants, Registrants, and Parties at TTAB to Be Represented by U.S. Attorney
Blog April 2, 2018
USPTO Pilot Program Regarding Specimen Authenticity
Blog July 5, 2017
U.S. Trademark Office Clarifies Filing Deadlines for Resurrecting Dead Applications and Registrations
Blog June 8, 2017
Even GOOGLE Can Google After All
Blog May 19, 2017
What Does The "In" in "Incontestable" Mean?
Blog February 7, 2017
U.S. Trademark Office Sharpens Machete for Pruning Deadwood
Blog February 3, 2017
FDA Final Guidance on Nonproprietary Names of Biological Products
Article March 16, 2023
Attorneys Kristen McCallion and Darra Loganzo Co-Author World Trademark Review Article "Could AI Require Platforms to Do More to Prevent Infringement?"
Article March 8, 2023
Senior Principal Terry Mahn Authors Medical Device + Diagnostic Industry Article "This Company's False Compliance With CISPR 11 Resulted in a $12 Million FCA...
Article February 17, 2023
Principals Patrick Darno and Peter Fasse Author "Patent Strategies for Protecting Bioinformatics Inventions" for IAM
Article February 3, 2023
Fish & Richardson Attorneys Author IAM Article "Neglect Begets Opportunity in Femtech IP"
Blog January 17, 2023
Biosimilars 2022 Year in Review
Article October 20, 2022
Life Sciences Entrepreneur Sourcebook | Intellectual Property: What It Is and Why You Should Care
Blog September 15, 2022
Legal Alert: What to Know About the USPTO's Duty of Candor Guidance Regarding FDA Submissions
Blog January 11, 2022
Biosimilars 2021 Year in Review
Article July 23, 2021
Fish Principal Cindy Walden Authors World IP Review Article "Brand Owner's Friend: the Lanham Act at 75"
Blog December 2, 2020